REPL
Replimune Group, Inc.
NASDAQ · Healthcare · Biotechnology · US
$15.04
−1.64%Margins
Gross margin
—
EBITDA margin
—
EBIT margin
—
Net margin
—
FCF margin
—
-281.1%
Return on equity
-117.7%
Return on assets
-136.8%
Return on invested capital
0.00x
Asset turnover
-$279.1M
Cash from operations
$2.07
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026